Cargando…

When should we order a next generation sequencing test in a patient with cancer?

Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although n...

Descripción completa

Detalles Bibliográficos
Autores principales: Colomer, Ramon, Mondejar, Rebeca, Romero-Laorden, Nuria, Alfranca, Arantzazu, Sanchez-Madrid, Francisco, Quintela-Fandino, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397394/
https://www.ncbi.nlm.nih.gov/pubmed/32775973
http://dx.doi.org/10.1016/j.eclinm.2020.100487
_version_ 1783565770288005120
author Colomer, Ramon
Mondejar, Rebeca
Romero-Laorden, Nuria
Alfranca, Arantzazu
Sanchez-Madrid, Francisco
Quintela-Fandino, Miguel
author_facet Colomer, Ramon
Mondejar, Rebeca
Romero-Laorden, Nuria
Alfranca, Arantzazu
Sanchez-Madrid, Francisco
Quintela-Fandino, Miguel
author_sort Colomer, Ramon
collection PubMed
description Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although new research results provide evidence favoring this approach in some types of advanced cancer. Clinical research is evolving rapidly, from basket and umbrella trials to adaptative design precision oncology clinical studies, and genomic and molecular data often displace the classical clinical validation procedures of biomarkers. In this context, physicians must be aware of the clinical evidence behind these new biomarkers and NGS tests available, in order to use them in the right moment, and with a critical point of view. This review will present the status of currently available targeted drugs that can be effective based on actionable molecular alterations, and the NGS tests that are currently available, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice.
format Online
Article
Text
id pubmed-7397394
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73973942020-08-06 When should we order a next generation sequencing test in a patient with cancer? Colomer, Ramon Mondejar, Rebeca Romero-Laorden, Nuria Alfranca, Arantzazu Sanchez-Madrid, Francisco Quintela-Fandino, Miguel EClinicalMedicine Review Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although new research results provide evidence favoring this approach in some types of advanced cancer. Clinical research is evolving rapidly, from basket and umbrella trials to adaptative design precision oncology clinical studies, and genomic and molecular data often displace the classical clinical validation procedures of biomarkers. In this context, physicians must be aware of the clinical evidence behind these new biomarkers and NGS tests available, in order to use them in the right moment, and with a critical point of view. This review will present the status of currently available targeted drugs that can be effective based on actionable molecular alterations, and the NGS tests that are currently available, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice. Elsevier 2020-07-31 /pmc/articles/PMC7397394/ /pubmed/32775973 http://dx.doi.org/10.1016/j.eclinm.2020.100487 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Colomer, Ramon
Mondejar, Rebeca
Romero-Laorden, Nuria
Alfranca, Arantzazu
Sanchez-Madrid, Francisco
Quintela-Fandino, Miguel
When should we order a next generation sequencing test in a patient with cancer?
title When should we order a next generation sequencing test in a patient with cancer?
title_full When should we order a next generation sequencing test in a patient with cancer?
title_fullStr When should we order a next generation sequencing test in a patient with cancer?
title_full_unstemmed When should we order a next generation sequencing test in a patient with cancer?
title_short When should we order a next generation sequencing test in a patient with cancer?
title_sort when should we order a next generation sequencing test in a patient with cancer?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397394/
https://www.ncbi.nlm.nih.gov/pubmed/32775973
http://dx.doi.org/10.1016/j.eclinm.2020.100487
work_keys_str_mv AT colomerramon whenshouldweorderanextgenerationsequencingtestinapatientwithcancer
AT mondejarrebeca whenshouldweorderanextgenerationsequencingtestinapatientwithcancer
AT romerolaordennuria whenshouldweorderanextgenerationsequencingtestinapatientwithcancer
AT alfrancaarantzazu whenshouldweorderanextgenerationsequencingtestinapatientwithcancer
AT sanchezmadridfrancisco whenshouldweorderanextgenerationsequencingtestinapatientwithcancer
AT quintelafandinomiguel whenshouldweorderanextgenerationsequencingtestinapatientwithcancer